J
Jeffrey H. Lipton
Researcher at Princess Margaret Cancer Centre
Publications - 498
Citations - 18615
Jeffrey H. Lipton is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Transplantation & Myeloid leukemia. The author has an hindex of 54, co-authored 449 publications receiving 16517 citations. Previous affiliations of Jeffrey H. Lipton include Canadian Blood Services & University Health Network.
Papers
More filters
Journal ArticleDOI
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani,Michael W. Deininger,Gianantonio Rosti,Andreas Hochhaus,Simona Soverini,Jane F. Apperley,Francisco Cervantes,Richard E. Clark,Jorge E. Cortes,François Guilhot,Henrik Hjorth-Hansen,Timothy P. Hughes,Hagop M. Kantarjian,Dong-Wook Kim,Richard A. Larson,Jeffrey H. Lipton,François Xavier Mahon,Giovanni Martinelli,Jiri Mayer,Martin C. Müller,Dietger Niederwieser,Fabrizio Pane,Jerald P. Radich,Philippe Rousselot,Giuseppe Saglio,Susanne Saußele,Charles A. Schiffer,Richard T. Silver,Bengt Simonsson,Juan Luis Steegmann,John M. Goldman,Rüdiger Hehlmann +31 more
TL;DR: Optimal responders to chronic myeloid leukemia treatment should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved.
Journal ArticleDOI
Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease
Andrew J. Ullmann,Jeffrey H. Lipton,David H. Vesole,Pranatharthi H. Chandrasekar,Amelia Langston,Stefano R. Tarantolo,Hildegard Greinix,Wellington Morais de Azevedo,Vijay Reddy,Navdeep Boparai,Lisa D. Pedicone,Hernando Patino,Simon Durrant +12 more
TL;DR: Posaconazole was similar to fluconazole for prophylaxis against fungal infections among patients with GVHD and was superior in preventing invasive aspergillosis and reducing the rate of deaths related toFungal infections.
Journal ArticleDOI
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Timothy P. Hughes,Michael W. Deininger,Andreas Hochhaus,Susan Branford,Jerald P. Radich,Jaspal Kaeda,Michele Baccarani,Jorge E. Cortes,Nicholas C.P. Cross,Brian J. Druker,Jean Gabert,David Grimwade,Rüdiger Hehlmann,Suzanne Kamel-Reid,Jeffrey H. Lipton,Janina A. Longtine,Giovanni Martinelli,Giuseppe Saglio,Simona Soverini,Wendy Stock,John M. Goldman +20 more
TL;DR: Suggestions are made for harmonizing the differing methodologies for measuring BCR-ABL transcripts in patients with CML undergoing treatment and using a conversion factor whereby individual laboratories can express BCR -ABL transcript levels on an internationally agreed scale.
Journal ArticleDOI
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Andreas Hochhaus,Michele Baccarani,Richard T. Silver,Charles A. Schiffer,Jane F. Apperley,Francisco Cervantes,Richard E. Clark,Jorge E. Cortes,Michael W. Deininger,François Guilhot,Henrik Hjorth-Hansen,Timothy P. Hughes,Jeroen Janssen,Hagop M. Kantarjian,Dong-Wook Kim,Richard A. Larson,Jeffrey H. Lipton,Francois-Xavier Mahon,Jiří Mayer,Franck E. Nicolini,Dietger Niederwieser,Fabrizio Pane,Jerald P. Radich,Delphine Rea,Johan Richter,Gianantonio Rosti,Philippe Rousselot,Giuseppe Saglio,Susanne Saußele,Simona Soverini,Juan Luis Steegmann,Anna G. Turkina,Andrey Zaritskey,Ruediger Hehlmann +33 more
TL;DR: An expert panel to critically evaluate and update the evidence to achieve goals to achieve a stable deep molecular response (DMR) and discontinuing medication for treatment-free remission (TFR) in chronic myeloid leukemia.
Journal ArticleDOI
Micafungin versus Fluconazole for Prophylaxis against Invasive Fungal Infections during Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation
Jo Anne H. Van Burik,Voravit Ratanatharathorn,Daniel E. Stepan,Carole B. Miller,Jeffrey H. Lipton,David H. Vesole,Nancy Bunin,Donna A. Wall,John W. Hiemenz,Yoichi Satoi,Jeanette M. Lee,Thomas J. Walsh +11 more
TL;DR: The overall efficacy of micafungin was superior to that of fluconazole as antifungal prophylaxis during the neutropenic phase after HSCT and this randomized trial demonstrates the efficacy of an echinocandin for antifundal proplylaxis in neutropenia patients.